On the heels of warnings from the U.S. Food and Drug Administration about the risks of using power morcellators in uterine surgery, the Judicial Panel on Multidistrict Litigation has been asked to consolidate 21 federal suits against makers of the devices—and lawyers involved in the litigation predict that while the number of cases will not be large, their value could be significant.

Plaintiffs in power morcellator cases tend to have major medical bills and most are within the peak earning years of 40 to 60, according to those lawyers.

Patients with undiagnosed uterine cancer who undergo a hysterectomy or removal of fibroids performed with a power morcellator risk spreading cancerous cells within their abdomen and pelvis, reducing their chances of long-term survival, the FDA announced in April 2014. Now, suits are being filed nationwide against the companies that made the morcellators by women who underwent such procedures, or by the survivors of women who died after their operations.